Sort
10,766 grants matching “checkpoint inhibitor”
SBIR Phase I: Anti-Tumor Immune Redirectors (AIRs) for cancer treatment
$225,000Joshua Wang · Pathovax · · FY2018 · TIP
Predevelopment of VV2003, a Novel CRAC Channel Inhibitor, to Improve Outcomes Associated with Checkpoint Inhibitor Immunotherapy
$225,000Milton L Greenberg · Vivreon Biosciences, Llc · R43 · FY2018 · CA
Small-molecule agonists of the RIG-I-like receptor pathway as cancer immunotherapeutics
$225,000Peter Probst · Kineta, Inc. · R43 · FY2018 · CA
Co-targeting Ezh2 with PD1 to improve T cell exhaustion reversal and tumor responses
$225,000Mumtaz Yaseen Balkhi · It Bio, Llc · R43 · FY2019 · CA
Small molecule ubiquitin ligase modulators for immunotherapy of cancer
$224,995Kumar Suresh · Progenra, Inc. · R43 · FY2017 · CA
Targeting TGF-beta activation in tumors
$224,981Bo Yu · Larix Bioscience, Llc · R43 · FY2019 · CA
Novel monobody therapy for pancreatic cancer
$224,981Bo Yu · Larix Bioscience, Llc · R43 · FY2017 · CA
Predevelopment of VV2003, a Novel CRAC Channel Inhibitor, to Improve Outcomes Associated with Checkpoint Inhibitor Immunotherapy
$224,700Milton L Greenberg · Vivreon Biosciences, Llc · R44 · FY2020 · CA
RAPAMYCIN BLOCKADE OF PROTEIN PHOSPHATASE SIGNALING
$224,588University Of Virginia Charlottesville · R01 · FY2003 · CA
RAPAMYCIN BLOCKADE OF PROTEIN PHOSPHATASE SIGNALING
$224,571University Of Virginia Charlottesville · R01 · FY2004 · CA
Reversible vitamin A-dependent arrest of spermatogonia
$224,547James K Tsuruta · Univ Of North Carolina Chapel Hill · R01 · FY2006 · HD
SBIR Phase I: Highly Specific Flex-Hinge Antibody-Like Checkpoint Inhibitors for Safer and More Effective Cancer Therapy
$224,455Daniel J Capon · Hinge Bio, Inc. · · FY2018 · TIP
Special Public T Cell Receptor Sequences that Predict Outcomes for Cancer Patients
$224,400Seth M Pollack · Northwestern University At Chicago · R21 · FY2023 · CA
(PQ6): Is Adrenergic Stress-induced Immune Suppression at the Crossroads of Circadian Rhythm Disruption and Cancer?
$224,199Elizabeth Repasky · Roswell Park Cancer Institute Corp · R21 · FY2018 · CA
Specificity of the Ubiquitin System in Lymphoid Malignancies
$224,099Luca Busino · University Of Pennsylvania · R00 · FY2014 · CA
NAAA Inhibitors for pain and inflammation
$223,903Roger Heim · Anteana Therapeutics, Inc. · R43 · FY2015 · NS
Highly Multiplexed Analysis of Solid Tumors and Liquid Tissues by Cyclic Immunofluorescence
$223,840Eric Kaldjian · Rarecyte, Inc. · R41 · FY2018 · CA
P3: Molecular Mechanisms Underlying Therapy Response to Radiation and Immune Checkpoint BlockadeýSUBAWARD
$223,801David Sung-Wen Yu · Cleveland Clinic Lerner Com-Cwru · U54 · FY2025 · CA
Nitrosourea-induced growth arrest and apoptotic pathways
$223,778Kevin D Brown · University Of Florida · R01 · FY2006 · CA
Cell-based assay directly monitoring RNA Polymerase I activity for cancer drug discovery
$223,700Ryan O'Hanlon · Lucerna, Inc. · R43 · FY2020 · CA
Genomics Core
$223,652Jaroslav Jelinek · Coriell Institute For Medical Research · P50 · FY2021 · CA
INTERACTION OF YEAST CHECKPOINT PROTEINS AS DRUG ASSAY
$223,650University Of North Texas Hlth Sci Ctr · R01 · FY2004 · CA
Delivering miR-29a to enhance anti-viral and anti-tumor responses in vivo
$223,343Erietta Stelekati · University Of Miami School Of Medicine · R21 · FY2025 · AI
A Phase 1 Clinical Trial Evaluating the Novel Small Molecule Immuno-Oncology Antagonist SX-682 Alone and With Pembrolizumab in Metastatic Melanoma
$223,334Stuart J Kahn · Syntrix Biosystems, Inc. · R44 · FY2020 · CA
IGF::OT::IGF SBIR PHASE I TOPIC 354-A NOVEL PREDICTIVE TEST FOR RESPONSE TO IMMUNOTHERAPIES FOR PATIENTS WITH NON-SMALL CELL LUNG CANCER; POP 09/19/16-06/18/17
$223,063Greg Bertenshaw · Biomarker Strategies, Llc · N43 · FY2016 · CA